HUTCHISON CHINA MEDITECH LTD's ticker is HCM and the CUSIP is 44842L103. A total of 129 filers reported holding HUTCHISON CHINA MEDITECH LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $6,884,000 | -44.8% | 544,653 | -17.4% | 0.55% | -10.7% |
| Q1 2022 | $12,471,000 | -43.4% | 659,133 | +4.9% | 0.62% | -41.3% |
| Q4 2021 | $22,047,000 | -4.2% | 628,477 | 0.0% | 1.05% | -48.3% |
| Q3 2021 | $23,009,000 | +7.0% | 628,477 | +14.7% | 2.04% | +9.5% |
| Q2 2021 | $21,510,000 | +39.0% | 547,743 | 0.0% | 1.86% | +25.8% |
| Q1 2021 | $15,474,000 | -15.3% | 547,743 | -4.0% | 1.48% | -22.6% |
| Q4 2020 | $18,267,000 | -2.0% | 570,500 | -1.1% | 1.91% | -16.5% |
| Q3 2020 | $18,631,000 | +12.7% | 576,818 | -3.8% | 2.29% | +4.0% |
| Q2 2020 | $16,535,000 | +43.2% | 599,528 | -7.3% | 2.20% | +4.6% |
| Q1 2020 | $11,545,000 | -23.4% | 646,792 | +7.6% | 2.10% | -10.1% |
| Q4 2019 | $15,064,000 | +3.8% | 600,892 | -26.1% | 2.34% | -6.5% |
| Q3 2019 | $14,511,000 | -13.3% | 813,392 | +6.9% | 2.50% | +7.0% |
| Q2 2019 | $16,746,000 | -5.2% | 761,171 | +31.7% | 2.34% | +5.8% |
| Q1 2019 | $17,668,000 | – | 577,755 | – | 2.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Zeal Asset Management Ltd | 2,339,885 | $93,421,000 | 21.31% |
| UG Investment Advisers Ltd. | 33,155 | $1,302,000 | 2.52% |
| Pinz Capital Management, LP | 159,400 | $6,260,000 | 1.88% |
| Capital International Sarl | 547,743 | $21,510,000 | 1.86% |
| Capital International, Inc./CA/ | 4,391,684 | $172,461,000 | 1.54% |
| AIA Group Ltd | 437,118 | $17,380,000 | 1.20% |
| York Capital Management Global Advisors, LLC | 182,297 | $7,159,000 | 0.80% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 68,000 | $2,671,000 | 0.70% |
| E Fund Management (Hong Kong) Co., Ltd. | 18,579 | $730,000 | 0.46% |
| M&G INVESTMENT MANAGEMENT LTD | 4,512,562 | $175,990,000 | 0.44% |